Chargement en cours...
Efficacy and safety of Nivolumab in non-small cell lung cancer patients in Tel-Aviv tertiary medical center: Facing the reality
Nivolumab is a human IgG4 programmed death (PD)-1 immune checkpoint inhibitor antibody, which is approved in Israel for the treatment of patients with advanced non-small cell lung cancer (NSCLC). It is also administered to individuals with disease progression during or after platinum-based chemother...
Enregistré dans:
| Publié dans: | Mol Clin Oncol |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
D.A. Spandidos
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6125701/ https://ncbi.nlm.nih.gov/pubmed/30214730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2018.1693 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|